Association of linezolid interruption and rechallenge with clinical outcomes in patients with rifampicin-resistant tuberculosis in South Africa, 2018–22: an observational cohort study
The South African Medical Research Council, the European and Developing Countries Clinical Trials Partnership, and the National Research Foundation.
Authors
- Stuart Meier (ORCID: https://orcid.org/0000-0003-4559-9718)
- Suzette Oelofse (ORCID: https://orcid.org/0000-0001-7852-7804)
- Norbert Ndjeka (ORCID: https://orcid.org/0000-0001-6200-1592)
- Louié Kühn
- Tahlia Perumal (ORCID: https://orcid.org/0000-0003-0679-5804)
- Anil Pooran (ORCID: https://orcid.org/0000-0001-5808-433X)
- Shameem Z. Jaumdally (ORCID: https://orcid.org/0000-0003-0316-7087)
- Jeremi Swanepoel (ORCID: https://orcid.org/0000-0002-9338-2911)
- Linda Mbuthini (ORCID: https://orcid.org/0000-0003-3442-1156)
- Alex Scott (ORCID: https://orcid.org/0000-0003-0647-607X)
- Dr Aliasgar Esmail
- Keertan Dheda
Institutions
- National Health Laboratory Service (ZA)
- Tshwane University of Technology (ZA)
- University of Cape Town (ZA)
Publication Details
- Journal
- The Lancet Global Health
- Published
- 2026-03-17
- DOI
- https://doi.org/10.1016/s2214-109x(25)00489-9
- Primary Topic
- Antimicrobial Resistance in Staphylococcus
- Type
- article
- Field-Weighted Citation Impact
- 0.00